Raising blood levels of AAT with augmentation therapy is reported to prevent T1D development, prolong islet allograft survival [48], increase insulin release capacity [49], and inhibit pancreatic β-cell apoptosis [50]. The gene discussed is SERPINA1; the disease is type 1 diabetes mellitus.